Skip to content
United States

News Releases

  1. Home
  2. News & Media
  3. News Releases
Category
Year
Filters applied:
  • September 24, 2026
  • General
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
  • August 24, 2026
  • General
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
  • August 4, 2026
  • Earnings
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
  • July 30, 2026
  • General
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
  • July 20, 2026
  • General
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
  • July 15, 2026
  • General
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
  • July 6, 2026
  • General
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
  • June 26, 2026
  • General
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
  • May 6, 2026
  • General
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
  • April 30, 2026
  • General
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
  • April 28, 2026
  • General
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
  • April 17, 2026
  • General
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
  • April 15, 2026
  • General
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
  • April 7, 2026
  • General
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
  • March 12, 2026
  • General
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
  • March 3, 2026
  • General
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
  • March 2, 2026
  • General
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
  • February 25, 2026
  • Earnings
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
  • February 23, 2026
  • General
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
  • February 4, 2026
  • General
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
  • February 2, 2026
  • General
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
  • January 13, 2026
  • General
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
  • December 18, 2025
  • General
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
  • December 12, 2025
  • General
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
  • November 20, 2025
  • General
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
  • November 5, 2025
  • Earnings
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
  • October 28, 2025
  • General
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
  • October 15, 2025
  • General
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
  • October 2, 2025
  • General
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
  • September 24, 2025
  • General
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
  • September 12, 2025
  • General
Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
  • September 8, 2025
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • August 26, 2025
  • General
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
  • August 25, 2025
  • General
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
  • August 11, 2025
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • August 6, 2025
  • Earnings
Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview
  • August 5, 2025
  • General
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
  • August 4, 2025
  • General
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer
  • July 23, 2025
  • General
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025
  • July 3, 2025
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • June 25, 2025
  • General
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
  • June 17, 2025
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • June 9, 2025
  • General
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
  • June 5, 2025
  • General
Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025
  • May 29, 2025
  • General
Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
  • May 27, 2025
  • General
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise
  • May 20, 2025
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • May 16, 2025
  • General
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation
  • May 7, 2025
  • Earnings
Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview
  • May 5, 2025
  • General
Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference
  • April 23, 2025
  • General
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025
  • April 11, 2025
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • March 14, 2025
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • March 13, 2025
  • General
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
  • March 5, 2025
  • General
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
  • March 3, 2025
  • General
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
  • February 27, 2025
  • General
Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference
  • February 26, 2025
  • Earnings
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
  • February 14, 2025
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • February 12, 2025
  • General
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
  • January 17, 2025
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • January 14, 2025
  • General
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
  • January 14, 2025
  • General
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
  • December 19, 2024
  • General
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
  • December 16, 2024
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • December 11, 2024
  • General
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
  • December 9, 2024
  • General
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
  • November 26, 2024
  • General
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
  • November 21, 2024
  • General
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
  • November 15, 2024
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • November 6, 2024
  • Earnings
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
  • November 5, 2024
  • General
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
  • October 17, 2024
  • General
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
  • October 16, 2024
  • General
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
  • October 8, 2024
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • September 26, 2024
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • September 23, 2024
  • General
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
  • August 28, 2024
  • General
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
  • August 14, 2024
  • General
Ryan Reynolds Announces More to Parkinson’s® Campaign
  • August 7, 2024
  • General
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
  • August 6, 2024
  • Earnings
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
  • July 24, 2024
  • General
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
  • July 18, 2024
  • General
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
  • June 18, 2024
  • General
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
  • May 17, 2024
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • May 15, 2024
  • General
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
  • May 9, 2024
  • General
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
  • May 8, 2024
  • Earnings
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
  • April 29, 2024
  • General
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
  • April 24, 2024
  • General
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
  • April 22, 2024
  • General
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
  • April 19, 2024
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • April 17, 2024
  • General
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
  • April 2, 2024
  • General
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
  • April 1, 2024
  • General
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
  • March 15, 2024
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • March 13, 2024
  • General
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
  • March 11, 2024
  • General
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
  • February 29, 2024
  • General
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
  • February 27, 2024
  • Earnings
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
  • February 21, 2024
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • February 13, 2024
  • General
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
  • January 31, 2024
  • General
Acadia Announces Additions to Executive Team
  • January 19, 2024
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • January 18, 2024
  • General
Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic
  • December 21, 2023
  • General
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
  • December 18, 2023
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • December 14, 2023
  • General
Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)
  • December 13, 2023
  • General
Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation
  • November 30, 2023
  • General
Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome
  • November 27, 2023
  • General
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
  • November 21, 2023
  • General
Acadia Pharmaceuticals Announces Change in Research and Development Leadership
  • November 14, 2023
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • November 2, 2023
  • Earnings
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
  • October 31, 2023
  • General
Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference
  • October 23, 2023
  • General
Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program
  • October 19, 2023
  • General
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023
  • October 18, 2023
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • September 22, 2023
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • September 19, 2023
  • General
Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
  • September 18, 2023
  • Company Statement
Acadia Pharmaceuticals Announces Label Update for NUPLAZID® (pimavanserin)
  • August 30, 2023
  • General
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
  • August 14, 2023
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • August 2, 2023
  • Earnings
Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview
  • August 1, 2023
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • July 24, 2023
  • General
Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer
  • July 19, 2023
  • General
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023
  • July 13, 2023
  • General
Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome
  • June 26, 2023
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • June 13, 2023
  • General
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome
  • June 8, 2023
  • General
Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome
  • June 1, 2023
  • General
Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
  • May 8, 2023
  • Earnings
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
  • May 5, 2023
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • May 2, 2023
  • General
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
  • April 25, 2023
  • General
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023
  • April 20, 2023
  • General
Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
  • April 17, 2023
  • General
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
  • April 11, 2023
  • General
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
  • March 11, 2023
  • General
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
  • February 27, 2023
  • Earnings
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
  • February 14, 2023
  • General
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
  • February 13, 2023
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • January 9, 2023
  • General
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
  • January 3, 2023
  • General
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics
  • December 21, 2022
  • General
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
  • November 8, 2022
  • General
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
  • November 2, 2022
  • Earnings
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
  • October 27, 2022
  • General
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
  • October 20, 2022
  • General
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
  • October 13, 2022
  • General
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
  • October 4, 2022
  • General
Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed
  • September 12, 2022
  • General
Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA
  • September 1, 2022
  • General
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
  • August 8, 2022
  • Earnings
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
  • August 5, 2022
  • General
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
  • July 25, 2022
  • General
Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022
  • July 18, 2022
  • General
Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
  • June 18, 2022
  • General
Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
  • June 17, 2022
  • General
Acadia Pharmaceuticals Stock Trading Halted Today
  • May 4, 2022
  • Earnings
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
  • May 3, 2022
  • General
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
  • May 2, 2022
  • General
Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022
  • April 21, 2022
  • General
Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022
  • April 18, 2022
  • General
Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain
  • March 22, 2022
  • General
Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)
  • March 10, 2022
  • General
Acadia Pharmaceuticals to Present at the 1st Annual Needham Virtual Neuroscience Forum on March 16, 2022
  • March 9, 2022
  • General
Acadia Pharmaceuticals Announces August 4, 2022 Action Date for Resubmitted Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
  • March 3, 2022
  • General
Acadia Pharmaceuticals to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022
  • February 28, 2022
  • Earnings
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
  • February 16, 2022
  • General
Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis
  • February 14, 2022
  • General
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
  • February 11, 2022
  • General
Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022
  • January 10, 2022
  • General
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
  • December 22, 2021
  • General
Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
  • December 20, 2021
  • General
Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)
  • December 14, 2021
  • General
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer
  • December 6, 2021
  • General
Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
  • December 1, 2021
  • General
The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia
  • November 16, 2021
  • General
Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson’s Disease Non-Motor Symptoms
  • November 8, 2021
  • Earnings
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
  • November 2, 2021
  • General
Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021
  • November 1, 2021
  • General
Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
  • October 27, 2021
  • General
Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021
  • October 25, 2021
  • General
Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
  • September 2, 2021
  • General
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
  • September 1, 2021
  • General
Acadia Pharmaceuticals Announces Executive Leadership Change
  • August 5, 2021
  • General
Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021
  • August 4, 2021
  • Earnings
Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results
  • July 21, 2021
  • General
The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis
  • July 21, 2021
  • General
Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021
  • July 14, 2021
  • General
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC)
  • June 3, 2021
  • General
NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders
  • May 26, 2021
  • General
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
  • May 5, 2021
  • Earnings
Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results
  • May 4, 2021
  • General
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
  • April 21, 2021
  • General
Acadia Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021
  • April 5, 2021
  • General
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
  • March 8, 2021
  • General
Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
  • February 24, 2021
  • Earnings
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
  • February 19, 2021
  • General
Acadia Pharmaceuticals Recognizes National Caregiver’s Day with Launch of MoreThanMemoryLoss.com
  • February 18, 2021
  • General
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
  • February 10, 2021
  • General
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
  • January 27, 2021
  • General
Acadia Pharmaceuticals Announces Commercial Leadership Change
  • December 22, 2020
  • General
Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021
  • November 10, 2020
  • General
Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020
  • November 4, 2020
  • Earnings
Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results
  • October 26, 2020
  • General
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference
  • October 21, 2020
  • General
Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020
  • October 14, 2020
  • General
The Lewy Body Dementia Association and Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Williams Documentary, “Robin’s Wish”
  • October 6, 2020
  • General
Michael J. Fox Foundation and Acadia Pharmaceuticals Partner to Share Resources and Foster Dialogue on Cognitive Changes and Other Non-Motor Symptoms in Parkinson’s Disease
  • October 1, 2020
  • General
Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors
  • September 2, 2020
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • August 31, 2020
  • General
ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development
  • August 25, 2020
  • General
ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio
  • August 12, 2020
  • General
ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020
  • August 5, 2020
  • Earnings
ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
  • July 29, 2020
  • General
People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights
  • July 22, 2020
  • General
ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
  • July 20, 2020
  • General
ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
  • July 20, 2020
  • General
ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
  • June 15, 2020
  • General
ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
  • June 2, 2020
  • General
ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020
  • May 28, 2020
  • General
ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
  • May 26, 2020
  • General
ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
  • May 21, 2020
  • General
ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting
  • May 7, 2020
  • Earnings
ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
  • May 7, 2020
  • General
ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration
  • May 5, 2020
  • General
ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
  • April 15, 2020
  • General
ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020
  • March 3, 2020
  • General
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome
  • February 26, 2020
  • Earnings
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
  • February 24, 2020
  • General
ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020
  • February 12, 2020
  • General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020
  • January 7, 2020
  • General
ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020
  • December 18, 2019
  • General
ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer
  • December 5, 2019
  • General
ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
  • November 25, 2019
  • General
ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia
  • November 11, 2019
  • General
ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 4, 2019
  • November 4, 2019
  • General
ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer
  • October 30, 2019
  • General
ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder
  • October 30, 2019
  • Earnings
ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results
  • October 16, 2019
  • General
ACADIA Pharmaceuticals to Announce Third Quarter 2019 Financial Results on October 30, 2019
  • October 7, 2019
  • General
ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress
  • October 3, 2019
  • General
ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Meeting
  • September 25, 2019
  • General
ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019
  • September 24, 2019
  • General
ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder
  • September 23, 2019
  • General
ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson’s Disease and Movement Disorders
  • September 20, 2019
  • General
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  • September 19, 2019
  • General
ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings
  • September 18, 2019
  • General
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
  • September 17, 2019
  • General
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
  • September 9, 2019
  • General
ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis
  • September 4, 2019
  • General
ACADIA Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 11, 2019
  • July 31, 2019
  • Earnings
ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results
  • July 22, 2019
  • General
ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia
  • July 17, 2019
  • General
ACADIA Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019
  • June 25, 2019
  • General
New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partners
  • June 4, 2019
  • General
ACADIA Pharmaceuticals to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
  • May 18, 2019
  • General
ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting
  • May 7, 2019
  • General
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019
  • May 1, 2019
  • Earnings
ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
  • April 25, 2019
  • General
ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder
  • April 17, 2019
  • General
ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
  • April 11, 2019
  • General
ACADIA Pharmaceuticals Supports Parkinson’s Disease Awareness Month and World Parkinson’s Day with Local Educational Initiatives and Community Events Across the Country
  • April 2, 2019
  • General
ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019
  • April 1, 2019
  • General
ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer
  • March 27, 2019
  • General
Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology
  • March 4, 2019
  • General
ACADIA Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on March 11, 2019
  • February 26, 2019
  • Earnings
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
  • February 21, 2019
  • General
ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
  • February 12, 2019
  • General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019
  • December 20, 2018
  • General
ACADIA Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
  • November 30, 2018
  • General
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  • November 28, 2018
  • General
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
  • November 26, 2018
  • General
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
  • November 6, 2018
  • Earnings
ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results
  • October 31, 2018
  • General
ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)
  • October 29, 2018
  • General
ACADIA Pharmaceuticals Announces Executive Leadership Change
  • October 23, 2018
  • General
ACADIA Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 6, 2018
  • September 26, 2018
  • General
ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and Science
  • September 25, 2018
  • General
ACADIA Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference on October 2, 2018
  • September 20, 2018
  • General
FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
  • September 10, 2018
  • General
Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s Disease Psychosis and Parkinson’s Disease Psychosis Published in The Journal of Prevention of Alzheimer’s Disease Suggest Potential for Treating Dementia-Related Psychosis
  • September 4, 2018
  • General
ACADIA Pharmaceuticals to Present at the Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018
  • August 8, 2018
  • Earnings
ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results
  • August 6, 2018
  • General
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome
  • July 30, 2018
  • General
ACADIA Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 8, 2018
  • July 19, 2018
  • General
ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary
  • June 29, 2018
  • General
ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin)
  • June 13, 2018
  • General
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 20, 2018
  • June 6, 2018
  • General
ACADIA Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on June 13, 2018
  • May 8, 2018
  • General
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018
  • May 4, 2018
  • Earnings
ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results
  • May 2, 2018
  • General
ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations
  • May 1, 2018
  • General
ACADIA Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 4, 2018
  • April 27, 2018
  • General
ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting
  • April 27, 2018
  • General
ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID
  • April 23, 2018
  • General
PMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinson’s Disease
  • March 20, 2018
  • General
ACADIA Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018
  • March 6, 2018
  • General
ACADIA Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference on March 13, 2018
  • February 27, 2018
  • Earnings
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
  • February 20, 2018
  • General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018
  • January 2, 2018
  • General
ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018
  • December 13, 2017
  • General
ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development
  • November 21, 2017
  • General
ACADIA Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28, 2017
  • November 7, 2017
  • Earnings
ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results
  • November 3, 2017
  • General
ACADIA Pharmaceuticals Presents Data from the Phase II Study of Pimavanserin in Alzheimer’s Disease Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2017 Meeting
  • October 31, 2017
  • General
ACADIA Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017
  • October 4, 2017
  • General
ACADIA Pharmaceuticals Initiates Phase III Study of Pimavanserin in Dementia-Related Psychosis
  • September 19, 2017
  • General
ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017
  • August 8, 2017
  • Earnings
ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results
  • August 1, 2017
  • General
ACADIA Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 8, 2017
  • July 25, 2017
  • General
ACADIA Pharmaceuticals Named to Forbes Magazine’s List of World’s Most Innovative Growth Companies
  • May 9, 2017
  • Earnings
ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results
  • May 8, 2017
  • General
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference on May 16, 2017
  • May 2, 2017
  • General
ACADIA Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 9, 2017
  • March 30, 2017
  • General
ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer
  • March 29, 2017
  • General
ACADIA Pharmaceuticals to Present at Needham & Company’s 16th Annual Healthcare Conference on April 5, 2017
  • February 28, 2017
  • Earnings
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
  • February 27, 2017
  • General
ACADIA Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6, 2017
  • February 21, 2017
  • General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017
  • January 3, 2017
  • General
ACADIA Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 10, 2017
  • December 20, 2016
  • General
ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study of Pimavanserin for Alzheimer’s Disease Psychosis
  • December 1, 2016
  • General
ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Major Depressive Disorder
  • November 15, 2016
  • General
ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Negative Symptoms of Schizophrenia
  • November 7, 2016
  • Earnings
ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results
  • November 3, 2016
  • General
ACADIA Pharmaceuticals Initiates Phase III Trial of Pimavanserin for Adjunctive Treatment in Patients with Schizophrenia
  • November 1, 2016
  • General
ACADIA Pharmaceuticals to Announce Third Quarter 2016 Financial Results on November 7, 2016
  • October 31, 2016
  • General
ACADIA Pharmaceuticals Initiates Phase II Study of Pimavanserin in Alzheimer’s Disease Agitation
  • October 11, 2016
  • General
ACADIA Pharmaceuticals Receives California Life Sciences Association’s 2016 Pantheon DiNA Award for Outstanding Therapeutic Product for NUPLAZID™
  • September 20, 2016
  • General
ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016
  • September 19, 2016
  • General
ACADIA Pharmaceuticals Sponsors National Parkinson Foundation’s Caregiver Summit
  • September 6, 2016
  • General
ACADIA Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2016
  • August 24, 2016
  • General
ACADIA Pharmaceuticals Announces Appointment of Todd S. Young as Executive Vice President, Chief Financial Officer
  • August 23, 2016
  • General
ACADIA Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
  • August 10, 2016
  • General
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
  • August 8, 2016
  • General
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
  • August 4, 2016
  • Earnings
ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results
  • July 29, 2016
  • General
ACADIA Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016
  • June 27, 2016
  • General
ACADIA Pharmaceuticals Added to Large-Cap Russell 1000 Market Index
  • June 16, 2016
  • General
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016
  • June 1, 2016
  • General
ACADIA Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016
  • May 31, 2016
  • General
ACADIA Pharmaceuticals Announces NUPLAZID™ (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
  • May 5, 2016
  • Earnings
ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results
  • May 4, 2016
  • General
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016
  • May 2, 2016
  • General
ACADIA Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 5, 2016
  • April 29, 2016
  • General
FDA Approves ACADIA Pharmaceuticals’ NUPLAZID™ (pimavanserin) - The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
  • April 6, 2016
  • General
ACADIA Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016
  • March 29, 2016
  • General
FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
  • March 29, 2016
  • General
ACADIA Pharmaceuticals Stock Trading Halted Today
  • March 1, 2016
  • General
ACADIA Pharmaceuticals to Present at the Cowen and Company 36th Annual Health Care Conference on March 8, 2016
  • February 29, 2016
  • Earnings
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
  • February 23, 2016
  • General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016
  • February 3, 2016
  • General
ACADIA Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference on February 10, 2016
  • January 29, 2016
  • General
ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID™ (Pimavanserin) for the Treatment of Parkinson’s Disease Psychosis
  • January 25, 2016
  • General
ACADIA Pharmaceuticals Appoints James (Randy) R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer
  • January 11, 2016
  • General
ACADIA Pharmaceuticals Appoints Jim Daly to Board of Directors
  • January 7, 2016
  • General
ACADIA Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on January 12, 2016
  • January 7, 2016
  • General
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
  • January 5, 2016
  • General
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
  • December 15, 2015
  • General
ACADIA Pharmaceuticals Appoints Julian C. Baker to Board of Directors
  • November 30, 2015
  • General
ACADIA Pharmaceuticals Appoints Srdjan (Serge) Stankovic, M.D., M.S.P.H., as Executive Vice President, Head of Research and Development
  • November 30, 2015
  • General
ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., to Board of Directors
  • November 5, 2015
  • Earnings
ACADIA Pharmaceuticals Reports Third Quarter 2015 Financial Results
  • November 4, 2015
  • General
ACADIA Pharmaceuticals to Present at the 24th Annual Credit Suisse Healthcare Conference on November 10, 2015
  • November 2, 2015
  • General
ACADIA Pharmaceuticals Announces FDA Priority Review of NUPLAZID™ (Pimavanserin) New Drug Application for Parkinson’s Disease Psychosis
  • October 29, 2015
  • General
ACADIA Pharmaceuticals to Announce Third Quarter Financial Results on November 5, 2015
  • September 22, 2015
  • General
ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015
  • September 3, 2015
  • General
ACADIA Pharmaceuticals Appoints Steve Davis as Chief Executive Officer
  • September 3, 2015
  • General
ACADIA Pharmaceuticals Submits New Drug Application for NUPLAZID™ for the Treatment of Parkinson’s Disease Psychosis
  • August 6, 2015
  • General
ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results
  • August 6, 2015
  • General
ACADIA Pharmaceuticals Announces Publication of Data from Its -015 Open Label Safety Study in Parkinson’s Disease Psychosis in the Journal of the American Medical Directors Association
  • August 5, 2015
  • General
ACADIA Pharmaceuticals Announces Senior Management Appointments in Manufacturing, Quality, Compliance, Access and Reimbursement and Business Development
  • July 30, 2015
  • General
ACADIA Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2015
  • June 17, 2015
  • General
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 24, 2015
  • June 16, 2015
  • General
ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis at the 19th International Congress of Parkinson’s Disease and Movement Disorders
  • May 26, 2015
  • General
ACADIA Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference on June 2, 2015
  • May 7, 2015
  • General
ACADIA Pharmaceuticals Reports First Quarter 2015 Financial Results
  • May 6, 2015
  • General
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 13, 2015
  • April 30, 2015
  • General
ACADIA Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2015
  • April 7, 2015
  • General
ACADIA Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference on April 14, 2015
  • March 26, 2015
  • General
ACADIA Pharmaceuticals Appoints Daniel Soland to Board of Directors
  • March 11, 2015
  • General
ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer
  • March 11, 2015
  • General
ACADIA Pharmaceuticals Updates Planned Timing of NUPLAZID™ NDA Submission
  • February 26, 2015
  • General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014
  • February 24, 2015
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • February 19, 2015
  • General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015
  • January 6, 2015
  • General
ACADIA Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on January 13, 2015
  • December 8, 2014
  • General
ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson’s Disease and Related Disorders
  • November 25, 2014
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • November 13, 2014
  • General
ACADIA Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference on November 20, 2014
  • November 10, 2014
  • General
ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results and Updates Timing of NUPLAZID™ NDA Submission
  • November 3, 2014
  • General
ACADIA Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 10, 2014
  • September 2, 2014
  • General
ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis
  • August 28, 2014
  • General
ACADIA Pharmaceuticals Announces Trade Name NUPLAZID™ for Pimavanserin
  • August 5, 2014
  • General
ACADIA Pharmaceuticals Reports Second Quarter 2014 Financial Results
  • July 29, 2014
  • General
ACADIA Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 5, 2014
  • July 15, 2014
  • General
ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer
  • June 17, 2014
  • General
ACADIA Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference on June 24, 2014
  • May 27, 2014
  • General
ACADIA Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference on June 2, 2014
  • May 6, 2014
  • General
ACADIA Pharmaceuticals Reports First Quarter 2014 Financial Results
  • May 1, 2014
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • April 29, 2014
  • General
ACADIA Pharmaceuticals to Announce First Quarter 2014 Financial Results on May 6, 2014
  • April 1, 2014
  • General
ACADIA Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014
  • March 5, 2014
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • March 5, 2014
  • General
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
  • March 3, 2014
  • General
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
  • February 27, 2014
  • General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2013
  • February 20, 2014
  • General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
  • November 26, 2013
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • November 14, 2013
  • General
ACADIA Pharmaceuticals Announces Initiation of Phase II Trial with Pimavanserin for Alzheimer’s Disease Psychosis
  • November 6, 2013
  • General
ACADIA Pharmaceuticals Reports Third Quarter 2013 Financial Results
  • November 1, 2013
  • General
ACADIA Pharmaceuticals Announces Publication in The Lancet of Pivotal Phase III Parkinson’s Disease Psychosis Trial with Pimavanserin
  • October 30, 2013
  • General
ACADIA Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 6, 2013
  • September 3, 2013
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • August 19, 2013
  • General
ACADIA Pharmaceuticals Announces Appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer
  • August 6, 2013
  • General
ACADIA Pharmaceuticals Reports Second Quarter 2013 Financial Results
  • July 30, 2013
  • General
ACADIA Pharmaceuticals to Announce Second Quarter 2013 Financial Results on August 6, 2013
  • July 2, 2013
  • General
ACADIA Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference on July 9, 2013
  • July 1, 2013
  • General
ACADIA Pharmaceuticals Added to Russell 2000 Index
  • June 18, 2013
  • General
ACADIA Pharmaceuticals Announces Multiple Presentations of Data from Phase III Pimavanserin Program at the 17th International Congress of Parkinson’s Disease and Movement Disorders
  • June 3, 2013
  • General
ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical Development
  • May 29, 2013
  • General
ACADIA Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 5, 2013
  • May 20, 2013
  • General
ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
  • May 20, 2013
  • General
ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index
  • May 15, 2013
  • General
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
  • May 14, 2013
  • General
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
  • May 7, 2013
  • General
ACADIA Pharmaceuticals Reports First Quarter 2013 Financial Results
  • April 30, 2013
  • General
ACADIA Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 7, 2013
  • April 25, 2013
  • General
ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013
  • April 11, 2013
  • General
ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA
  • March 21, 2013
  • General
ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting
  • March 13, 2013
  • General
ACADIA Pharmaceuticals to Present at the 25th Annual ROTH Conference on March 19, 2013
  • March 12, 2013
  • General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
  • March 5, 2013
  • General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Financial Results on March 12, 2013
  • February 25, 2013
  • General
ACADIA Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013
  • February 5, 2013
  • General
ACADIA Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference on February 12, 2013
  • January 22, 2013
  • General
ACADIA Pharmaceuticals Announces Election of Stephen R. Biggar to Its Board of Directors
  • December 20, 2012
  • General
ACADIA Pharmaceuticals to Receive Funding from Fast Forward and EMD Serono for Multiple Sclerosis Program
  • December 12, 2012
  • General
ACADIA Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference Today, December 12, 2012
  • December 12, 2012
  • General
ACADIA Pharmaceuticals Announces $86 Million Equity Financing
  • November 27, 2012
  • General
ACADIA Announces Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinson’s Disease Psychosis Trial
  • November 26, 2012
  • General
ACADIA Pharmaceuticals to Host Conference Call and Webcast on November 27, 2012 at 8:00 AM EST to Present Top-Line Results from Its Pivotal Phase III Pimavanserin Parkinson’s Disease Psychosis Trial
  • November 5, 2012
  • General
ACADIA Pharmaceuticals Reports Third Quarter 2012 Financial Results
  • October 29, 2012
  • General
ACADIA Pharmaceuticals to Announce Third Quarter 2012 Financial Results on November 5, 2012
  • September 5, 2012
  • General
ACADIA Pharmaceuticals Announces Completion of Enrollment in Phase III Pimavanserin Trial in Parkinson’s Disease Psychosis
  • August 29, 2012
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • August 8, 2012
  • General
ACADIA Pharmaceuticals Reports Second Quarter 2012 Financial Results
  • August 1, 2012
  • General
ACADIA Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 8, 2012
  • July 9, 2012
  • General
ACADIA Pharmaceuticals Reports Promising Effects of Pimavanserin in Preclinical Model of Alzheimer’s Disease Psychosis
  • July 9, 2012
  • General
ACADIA Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference on July 13, 2012
  • May 15, 2012
  • General
ACADIA Pharmaceuticals to Webcast Educational Program on Parkinson’s Disease Psychosis on May 22, 2012
  • May 8, 2012
  • General
ACADIA Pharmaceuticals Reports First Quarter 2012 Financial Results
  • May 1, 2012
  • General
ACADIA Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 8, 2012
  • April 13, 2012
  • General
ACADIA Pharmaceuticals to Present at the 19th Annual Future Leaders in the Biotech Industry Conference on April 20, 2012
  • March 28, 2012
  • General
ACADIA Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference on April 3, 2012
  • March 27, 2012
  • General
ACADIA Pharmaceuticals Awarded New Grant from The Michael J. Fox Foundation for Development of Nurr1-RXR Selective Agonists to Treat Parkinson’s Disease
  • March 6, 2012
  • General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2011
  • March 5, 2012
  • General
ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.
  • February 29, 2012
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • February 28, 2012
  • General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2011 Financial Results on March 6, 2012
  • February 6, 2012
  • General
ACADIA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012
  • January 30, 2012
  • General
ACADIA Pharmaceuticals Announces Election of Bill Wells to Its Board of Directors
  • December 7, 2011
  • General
ACADIA Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 14, 2011
  • November 9, 2011
  • General
ACADIA Pharmaceuticals Reports Third Quarter 2011 Financial Results
  • November 7, 2011
  • General
ACADIA Pharmaceuticals Advances AM-831 to Phase I Clinical Development in Collaboration with Meiji Seika Pharma
  • November 2, 2011
  • General
ACADIA Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 9, 2011
  • September 21, 2011
  • General
ACADIA Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference on September 28, 2011
  • September 6, 2011
  • General
ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12, 2011
  • August 10, 2011
  • General
ACADIA Pharmaceuticals Reports Second Quarter 2011 Financial Results
  • August 3, 2011
  • General
ACADIA Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 10, 2011
  • May 17, 2011
  • General
ACADIA Pharmaceuticals Awarded Grant from National Institutes of Health for the Development of Novel ER-beta Agonists
  • May 10, 2011
  • General
ACADIA Pharmaceuticals Reports First Quarter 2011 Financial Results
  • May 4, 2011
  • General
ACADIA Pharmaceuticals to Present at the Tenth Annual JMP Securities Research Conference on May 11, 2011
  • May 3, 2011
  • General
ACADIA Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 10, 2011
  • April 1, 2011
  • General
ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.
  • March 29, 2011
  • General
ACADIA Pharmaceuticals to Present at the Tenth Annual Needham Healthcare Conference on April 5, 2011
  • March 10, 2011
  • General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2010
  • March 3, 2011
  • General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Financial Results on March 10, 2011
  • February 8, 2011
  • General
ACADIA Pharmaceuticals to Present at the Thirteenth Annual BIO CEO & Investor Conference on February 15, 2011
  • January 10, 2011
  • General
ACADIA Pharmaceuticals Announces $15 Million Private Placement
  • November 9, 2010
  • General
ACADIA Pharmaceuticals Reports Third Quarter 2010 Financial Results
  • November 9, 2010
  • General
ACADIA Pharmaceuticals Awarded Grant from The Michael J. Fox Foundation for the Development of Novel Nurr1-RXR Agonists to Treat Parkinson's Disease
  • November 2, 2010
  • General
ACADIA Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 9, 2010
  • October 28, 2010
  • General
ACADIA Pharmaceuticals Enters Agreement with Biovail to Conclude Collaboration and Regain North American Rights to Pimavanserin
  • September 22, 2010
  • General
ACADIA Pharmaceuticals to Present at the Fifth Annual JMP Securities Healthcare Conference on September 28, 2010
  • September 7, 2010
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • August 9, 2010
  • General
ACADIA Pharmaceuticals Reports Second Quarter 2010 Financial Results
  • August 2, 2010
  • General
ACADIA Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 9, 2010
  • July 29, 2010
  • General
ACADIA Pharmaceuticals Announces Initiation of New Phase III Trial with Pimavanserin for Parkinson's Disease Psychosis
  • June 2, 2010
  • General
ACADIA Pharmaceuticals To Present at the Ninth Annual Needham Healthcare Conference on June 9, 2010
  • May 10, 2010
  • General
ACADIA Pharmaceuticals Reports First Quarter 2010 Financial Results
  • May 5, 2010
  • General
ACADIA Pharmaceuticals to Present at the Ninth Annual JMP Securities Research Conference on May 12, 2010
  • May 3, 2010
  • General
ACADIA Pharmaceuticals to Announce First Quarter 2010 Financial Results on May 10, 2010
  • April 14, 2010
  • General
Dr. Joseph Friedman to Present Data From ACADIA Pharmaceuticals' First Phase III Trial With Pimavanserin for Parkinson's Disease Psychosis at the 62nd American Academy of Neurology Annual Meeting
  • March 9, 2010
  • General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2009
  • March 2, 2010
  • General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 9, 2010
  • February 1, 2010
  • General
ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 8, 2010
  • November 9, 2009
  • General
ACADIA Pharmaceuticals Reports Third Quarter 2009 Financial Results
  • November 2, 2009
  • General
ACADIA Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 9, 2009
  • October 20, 2009
  • General
ACADIA Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26, 2009
  • October 6, 2009
  • General
ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2009
  • October 6, 2009
  • General
ACADIA Pharmaceuticals Provides Update on Pimavanserin Collaborative Development Program
  • September 1, 2009
  • General
ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis
  • August 5, 2009
  • General
ACADIA Pharmaceuticals Reports Second Quarter 2009 Financial Results
  • July 29, 2009
  • General
ACADIA Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 5, 2009
  • June 3, 2009
  • General
ACADIA Pharmaceuticals to Present at the Eighth Annual Needham Life Sciences Conference on June 10, 2009
  • May 13, 2009
  • General
ACADIA Pharmaceuticals to Present at the Eighth Annual JMP Securities Research Conference on May 19, 2009
  • May 11, 2009
  • General
ACADIA Pharmaceuticals Reports First Quarter 2009 Financial Results
  • May 6, 2009
  • General
ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
  • May 5, 2009
  • General
ACADIA Pharmaceuticals to Announce First Quarter 2009 Financial Results on May 11, 2009
  • May 4, 2009
  • General
ACADIA Pharmaceuticals and Biovail Form Collaboration to Develop and Commercialize Pimavanserin in North America
  • March 25, 2009
  • General
ACADIA Pharmaceuticals and Meiji Seika Kaisha Form Collaboration to Develop and Commercialize a New Class of Pro-Cognitive Schizophrenia Drugs
  • March 9, 2009
  • General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2008
  • March 4, 2009
  • General
ACADIA Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference on March 11, 2009
  • March 2, 2009
  • General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
  • February 3, 2009
  • General
ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 10, 2009
  • January 7, 2009
  • General
ACADIA Pharmaceuticals Awarded Grant from The Michael J. Fox Foundation for the Development of Novel ER-beta Agonists for the Treatment of Parkinson’s Disease
  • November 25, 2008
  • General
ACADIA Pharmaceuticals to Present at The 20th Annual Piper Jaffray Health Care Conference on December 3, 2008
  • November 5, 2008
  • General
ACADIA Pharmaceuticals Reports Third Quarter 2008 Financial Results
  • November 3, 2008
  • General
ACADIA Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11, 2008
  • October 29, 2008
  • General
ACADIA Pharmaceuticals to Announce Third Quarter 2008 Financial Results on November 5, 2008
  • October 21, 2008
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • September 29, 2008
  • General
ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2008
  • September 5, 2008
  • General
ACADIA Pharmaceuticals Files Registration Statement as Required by Previously Announced Committed Equity Financing Facility
  • August 28, 2008
  • General
ACADIA Pharmaceuticals to Present at The Thomas Weisel Partners Healthcare Conference on September 4, 2008
  • August 5, 2008
  • General
ACADIA Pharmaceuticals Secures Committed Equity Financing Facility
  • August 5, 2008
  • General
ACADIA Pharmaceuticals Announces Second Quarter 2008 Financial Results and Strategic Restructuring
  • July 29, 2008
  • General
ACADIA Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
  • June 16, 2008
  • General
ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial
  • June 4, 2008
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • May 14, 2008
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • May 5, 2008
  • General
ACADIA Pharmaceuticals Reports First Quarter 2008 Financial Results
  • May 5, 2008
  • General
ACADIA Pharmaceuticals Announces Election of Laura A. Brege to Board of Directors
  • April 30, 2008
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • April 28, 2008
  • General
ACADIA Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 5, 2008
  • April 16, 2008
  • General
ACADIA Pharmaceuticals to Present Data from Its Phase II Trial with Pimavanserin for Parkinson's Disease Psychosis at the 60th American Academy of Neurology Annual Meeting
  • April 4, 2008
  • General
ACADIA Pharmaceuticals to Present Preclinical Data on ACP-104, ACP-105 and Its Muscarinic Discovery Program at Experimental Biology 2008 Meeting
  • March 31, 2008
  • General
ACADIA Pharmaceuticals Initiates Second Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
  • March 28, 2008
  • General
ACADIA Pharmaceuticals to Present at the 8th Annual Fortis Bank Biotechnology Conference
  • March 11, 2008
  • General
ACADIA Pharmaceuticals to Present at Lehman Brothers 11th Annual Global Healthcare Conference
  • March 5, 2008
  • General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007
  • February 27, 2008
  • General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 5, 2008
  • February 12, 2008
  • General
ACADIA Pharmaceuticals Appoints John J. Kaiser as Vice President, Strategic Marketing and Commercial Development
  • February 5, 2008
  • General
ACADIA Pharmaceuticals Announces Presentation of Data on Pimavanserin Co-Therapy at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
  • February 4, 2008
  • General
ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2008
  • December 26, 2007
  • General
ACADIA Pharmaceuticals to Present at the 26th Annual JP Morgan Healthcare Conference on January 7, 2008
  • December 14, 2007
  • General
ACADIA Pharmaceuticals Announces Completion of Enrollment of ACP-104 Phase IIb Clinical Trial Ahead of Schedule
  • December 6, 2007
  • General
ACADIA Pharmaceuticals to Webcast Its Analyst and Investor Meeting on December 14, 2007
  • November 7, 2007
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • November 5, 2007
  • General
ACADIA Pharmaceuticals Reports Third Quarter 2007 Financial Results
  • November 2, 2007
  • General
ACADIA Pharmaceuticals to Present Preclinical Data on Its Advanced Schizophrenia Programs at the 37th Annual Meeting of the Society for Neuroscience
  • October 29, 2007
  • General
ACADIA Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 5, 2007
  • October 26, 2007
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • October 3, 2007
  • General
ACADIA Pharmaceuticals to Present at BIO InvestorForum 2007 on October 10, 2007
  • September 25, 2007
  • General
ACADIA Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
  • September 19, 2007
  • General
ACADIA Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
  • August 6, 2007
  • General
ACADIA Pharmaceuticals Reports Second Quarter 2007 Financial Results
  • August 1, 2007
  • General
ACADIA Pharmaceuticals to Present at the Canaccord Adams 27th Annual Global Growth Conference
  • July 30, 2007
  • General
ACADIA Pharmaceuticals to Announce Second Quarter 2007 Financial Results on August 6, 2007
  • July 16, 2007
  • General
ACADIA Pharmaceuticals Earns Milestone on Advancement of Glaucoma Drug Candidate
  • June 26, 2007
  • General
ACADIA Pharmaceuticals Initiates Phase IIb Clinical Trial with ACP-104 in Patients with Schizophrenia
  • June 11, 2007
  • General
ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
  • May 24, 2007
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • May 8, 2007
  • General
ACADIA Pharmaceuticals Reports First Quarter 2007 Financial Results
  • May 1, 2007
  • General
ACADIA Pharmaceuticals to Announce First Quarter 2007 Financial Results on May 8, 2007
  • April 24, 2007
  • General
Pimavanserin Approved by USAN as Nonproprietary Name for ACADIA Drug Candidate ACP-103
  • April 20, 2007
  • General
ACADIA Pharmaceuticals Announces Exercise of Over-Allotment by Underwriters
  • April 18, 2007
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • April 4, 2007
  • General
ACADIA Pharmaceuticals Announces Pricing of Public Stock Offering
  • April 2, 2007
  • General
ACADIA Pharmaceuticals Announces Proposed Public Stock Offering
  • March 29, 2007
  • General
ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
  • March 19, 2007
  • General
ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial
  • March 14, 2007
  • General
ACADIA Pharmaceuticals to Present at Lehman Brothers 10th Annual Global Healthcare Conference
  • March 6, 2007
  • General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2006
  • February 27, 2007
  • General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2006 Financial Results on March 6, 2007
  • February 6, 2007
  • General
ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 13, 2007
  • January 3, 2007
  • General
ACADIA Pharmaceuticals to Present at the 25th Annual JP Morgan Healthcare Conference on January 11, 2007
  • December 4, 2006
  • General
ACADIA Pharmaceuticals Adds Complementary Intellectual Property for Serotonin Platform
  • November 6, 2006
  • General
ACADIA Pharmaceuticals Reports Third Quarter 2006 Financial Results
  • November 1, 2006
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • October 30, 2006
  • General
ACADIA Pharmaceuticals to Announce Third Quarter 2006 Financial Results on November 6, 2006
  • October 23, 2006
  • General
ACADIA Pharmaceuticals to Support Launch of New Company Focused on Substance Abuse Therapeutics
  • October 11, 2006
  • General
ACADIA Pharmaceuticals to Present at BIO InvestorForum 2006 on October 18, 2006
  • September 25, 2006
  • General
ACADIA Pharmaceuticals Announces Accelerated Timing of ACP-103 Phase II Trial in Patients with Schizophrenia; Top-Line Results for Complete 400-Patient Study Expected in Q1 2007
  • September 12, 2006
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • August 8, 2006
  • General
ACADIA Pharmaceuticals Reports Second Quarter 2006 Financial Results
  • August 3, 2006
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • August 2, 2006
  • General
ACADIA Pharmaceuticals to Announce Second Quarter 2006 Financial Results on August 8, 2006; ACADIA to Host Conference Call and Webcast on Tuesday, August 8, 2006, at 5:00 p.m. Eastern Time
  • July 13, 2006
  • General
ACADIA Pharmaceuticals Announces Encouraging Results from Initial Clinical Trials with ACP-104 in Patients with Schizophrenia
  • June 20, 2006
  • General
ACADIA Pharmaceuticals to Present at the Jefferies Life Sciences Conference on June 27, 2006
  • June 8, 2006
  • General
ACADIA Pharmaceuticals to Present at Needham's Fifth Annual Biotechnology and Medical Technology Conference
  • June 5, 2006
  • General
ACADIA Pharmaceuticals Announces Appointment of Roger G. Mills, M.D., as Executive Vice President, Development
  • May 15, 2006
  • General
ACADIA Pharmaceuticals Added to NASDAQ Biotech Index
  • May 10, 2006
  • General
ACADIA Pharmaceuticals Reports First Quarter 2006 Financial Results
  • May 8, 2006
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • May 3, 2006
  • General
ACADIA Pharmaceuticals to Announce First Quarter 2006 Financial Results on May 10, 2006
  • April 28, 2006
  • General
ACADIA Pharmaceuticals Announces Pricing of Public Stock Offering
  • April 24, 2006
  • General
ACADIA Pharmaceuticals Announces Proposed Public Stock Offering
  • April 19, 2006
  • General
ACADIA Pharmaceuticals Announces Positive Clinical Trial Results Demonstrating That ACP-103 Increases Slow Wave Sleep
  • March 23, 2006
  • General
ACADIA Pharmaceuticals Announces Positive Results From Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease
  • March 2, 2006
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • March 1, 2006
  • General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2005
  • February 22, 2006
  • General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2005 Results on March 1, 2006
  • February 21, 2006
  • General
ACADIA Pharmaceuticals Announces Advancements in Two Preclinical Programs
  • February 7, 2006
  • General
ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference 2006 on February 14, 2006
  • January 17, 2006
  • General
ACADIA Pharmaceuticals Announces Additional $10 Million Equity Investment by Sepracor
  • January 9, 2006
  • General
ACADIA Pharmaceuticals Announces Appointment of David C. Furlano, Ph.D., as Vice President, Regulatory Affairs
  • December 15, 2005
  • General
ACADIA Pharmaceuticals Discovers Novel Isoform-Selective Retinoic Acid Receptor Agonists
  • December 1, 2005
  • General
ACADIA Pharmaceuticals Reports Results From Phase II Study of ACP-103 in Schizophrenia Patients With Haloperidol-Induced Akathisia
  • November 10, 2005
  • General
ACADIA Pharmaceuticals Announces Initial Results From Ongoing Single-Dose Clinical Trial of ACP-104 in Schizophrenia Patients
  • November 10, 2005
  • General
Acadia Pharmaceuticals Reports Third Quarter 2005 Financial Results
  • November 3, 2005
  • General
ACADIA Pharmaceuticals to Announce Third Quarter 2005 Financial Results on November 10, 2005
  • November 1, 2005
  • General
ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on November 8, 2005
  • October 13, 2005
  • General
ACADIA Pharmaceuticals to Present at BIO InvestorForum 2005 on October 20, 2005
  • October 3, 2005
  • General
ACADIA Pharmaceuticals Earns Milestone on Advancement of Neuropathic Pain Clinical Program
  • September 22, 2005
  • General
ACADIA Pharmaceuticals Study Identifies Molecular Properties of ACP-104 That Predict Unique Antipsychotic Activity
  • September 20, 2005
  • General
ACADIA Pharmaceuticals to Present at the 2005 UBS Global Life Sciences Conference on September 27, 2005
  • September 16, 2005
  • General
ACADIA Pharmaceuticals Officially Opens New Chemistry R&D Facility in Sweden
  • September 13, 2005
  • General
ACADIA Pharmaceuticals Announces Election of Michael T. Borer to Board of Directors
  • August 24, 2005
  • General
ACADIA Pharmaceuticals Comments on Civil Litigation
  • August 17, 2005
  • General
ACADIA Pharmaceuticals to Present at the 8th Annual San Diego Growth Conference on August 19, 2005
  • August 10, 2005
  • General
ACADIA Pharmaceuticals Reports Second Quarter 2005 Financial Results
  • August 3, 2005
  • General
ACADIA Pharmaceuticals to Announce Second Quarter 2005 Financial Results on August 10, 2005
  • July 27, 2005
  • General
ACADIA Pharmaceuticals to Present at the 25th Annual Adams Harkness Summer Seminar on August 3, 2005
  • June 22, 2005
  • General
ACADIA Pharmaceuticals Announces Encouraging Interim Results From Ongoing Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease
  • May 19, 2005
  • General
ACADIA Pharmaceuticals to Present at the Fourth Annual Needham Biotechnology Conference
  • May 17, 2005
  • General
ACADIA Pharmaceuticals Expands Technology Platform to Target Tyrosine Kinase Linked Receptors
  • May 11, 2005
  • General
ACADIA Pharmaceuticals Reports First Quarter 2005 Financial Results
  • May 10, 2005
  • General
ACADIA Pharmaceuticals to Present at Banc of America Securities Health Care Conference 2005
  • May 4, 2005
  • General
ACADIA Pharmaceuticals to Announce First Quarter 2005 Financial Results on May 11, 2005
  • April 28, 2005
  • General
ACADIA Pharmaceuticals Announces Election of Mary Ann Gray, Ph.D. to Board of Directors
  • April 15, 2005
  • General
ACADIA Pharmaceuticals Announces $36 Million Financing
  • March 31, 2005
  • General
ACADIA Pharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference on April 7, 2005
  • March 7, 2005
  • General
ACADIA Announces Management Appointments in Business Development and Research and Development
  • March 3, 2005
  • General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2004
  • February 24, 2005
  • General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2004 Financial Results on March 3, 2005
  • February 22, 2005
  • General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
  • February 17, 2005
  • General
ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 24, 2005
  • January 19, 2005
  • General
ACADIA Pharmaceuticals to Present at the Piper Jaffray 17th Annual Health Care Conference on January 26, 2005
  • January 11, 2005
  • General
ACADIA Pharmaceuticals Announces Partnership With Sepracor
  • November 10, 2004
  • General
ACADIA Pharmaceuticals Reports Third Quarter 2004 Financial Results
  • November 4, 2004
  • General
ACADIA Pharmaceuticals Inc. Third Quarter 2004 Earnings Conference Call
  • November 3, 2004
  • General
ACADIA Pharmaceuticals to Announce Third Quarter 2004 Financial Results on November 10, 2004
  • October 26, 2004
  • General
ACADIA Pharmaceuticals Earns Milestone on Advancement of Neuropathic Pain Drug
  • October 19, 2004
  • General
ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference on October 26, 2004
  • October 7, 2004
  • General
ACADIA Pharmaceuticals to Present at the Bio Emerging Company Investor Forum
  • September 15, 2004
  • General
ACADIA Clinical Study Shows ACP-103 Improves Clinical Profile of Antipsychotic Drug Treatment
  • September 2, 2004
  • General
ACADIA Pharmaceuticals to Expand Scandinavian Chemistry Operations
  • August 11, 2004
  • General
ACADIA Pharmaceuticals Reports Second Quarter 2004 Financial Results
  • August 5, 2004
  • General
ACADIA Pharmaceuticals to Announce Second Quarter 2004 Financial Results on August 11, 2004
  • August 5, 2004
  • General
ACADIA Pharmaceuticals Inc. Second Quarter 2004 Earnings Conference Call
  • August 3, 2004
  • General
ACADIA Study Links ACP-104 (N-desmethylclozapine) to Improved Cognition in Schizophrenia Patients
  • July 30, 2004
  • General
ACADIA Pharmaceuticals to Present at the 24th Annual Adams Harkness Summer Seminar on August 5, 2004
  • June 29, 2004
  • General
ACADIA Pharmaceuticals Presents Favorable Results From Phase Ib/IIa Clinical Trial and PET Study of ACP-103
  • May 27, 2004
  • General
ACADIA Pharmaceuticals Announces Initial Public Offering
  • January 8, 2004
  • General
ACADIA Pharmaceuticals Achieves Milestone as Allergan Advances Glaucoma Drug Candidate
  • August 6, 2003
  • General
ACADIA Pharmaceuticals Successfully Completes Phase I Clinical Testing of ACP-103
  • June 12, 2003
  • General
ACADIA Pharmaceuticals Expands Private Placement to $28 Million
  • April 15, 2003
  • General
Allergan and ACADIA Pharmaceuticals Announce New Drug Discovery and Development Collaboration
  • March 28, 2003
  • General
ACADIA Pharmaceuticals Completes $25 Million Private Placement
  • January 22, 2003
  • General
ACADIA Initiates Clinical Trials for ACP-103 - Initially Targets Treatment-Induced Dysfunction in Parkinson's Disease
  • December 10, 2002
  • General
ACADIA Expands Pain Portfolio to Include New GPCR Targets
  • November 13, 2002
  • General
Paul S. Anderson, Ph.D., Appointed To ACADIA Pharmaceutical's Scientific Advisory Board
  • September 26, 2002
  • General
ACADIA Discovers Novel Small Molecule Leads for the V2 Vasopressin Receptor
  • June 13, 2002
  • General
ACADIA Applies Chemical Genomics to Discover Small Molecule Leads for Numerous GPCRs and Nuclear Rececptors
  • January 3, 2002
  • General
ACADIA Announces Chemical-Genomics Collaboration with Amgen to Discover Small Molecule Drugs
668 Results

Important Note

You are now being redirected

You are now leaving acadia.com

You are about to leave acadia.com. You will be redirected to a third party website not affiliated with Acadia Pharmaceuticals Inc.
Do you want to continue?

You are leaving our {{LEAVING_REGION}} website and going to our {{ENTERING_REGION}} website, which is in {{ENTERING_LANGUAGE}}.
The information you are about to be referred to may not comply with the local regulatory requirements.
Do you want to continue?

You are now being directed to another Acadia website that contains information about specific treatment(s).
Do you want to continue?

Continue